BioLineRX Ltd. · TASE:BLRX

BioLineRX — Investor Presentation (September 2011)

53 slides from BioLineRX's investor presentation, September 2011

  1. Slide 1: Company Presentation

    Slide 1: Company Presentation

    Company Presentation September 2011

  2. Slide 2: Forward Looking Statements

    Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains "forward-looking statements." These statements include words like "may," "expects," "believes," “plans,” “scheduled," and "intends," and describe opinions about future events. These forward-looking statements involve known and unknown risks and u

  3. Slide 3: Overview

    Slide 3: Overview

    OVERVIEW 3

  4. Slide 4: BioLineRx at a Glance

    Slide 4: BioLineRx at a Glance

    BioLineRx at a Glance • Founded in 2003 by Teva and other leaders in Israeli life sciences arena • Unique business model focused on “bench to bedside to partner” – Bridging development gap between promising compounds from universities and research labs, and international pharma companies • Unique ri

  5. Slide 5: BioLineRx at a Glance (cont.)

    Slide 5: BioLineRx at a Glance (cont.)

    BioLineRx at a Glance (cont.) • Clinical-stage company with 5 clinical assets – BL-1020 for schizophrenia - positive Phase IIb EAGLE study demonstrating cognition improvement • Highly efficacious with an enhanced safety profile • CLARITY Phase II/III clinical trial commenced June 2011 – BL-1040 for

  6. Slide 6: BioLineRx Business Model

    Slide 6: BioLineRx Business Model

    BioLineRx Business Model • Stringent selection and evaluation process – Established strategic relationships with all academic and research institutions in Israel – Use rigorous proprietary evaluation methodology to select compounds for in- licensing − >1300 compounds evaluated; 36 entered developmen

  7. Slide 7: Current Pipeline

    Slide 7: Current Pipeline

    Current Pipeline BL-1020 BL-1040 BL-5010 BL-1021 BL-7040 Pre-clinical BL-5040 BL-6010 BL-6020 BL-6030 BL-6040 BL-7010 BL-7020 BL-7030 Pre-Clinical Phase Ill Clinical Schizophrenia SS AM Out-licensed to Ikaria Holdings Inc. following completion of Phase I/II a Skin lesions Neuropathic pain Inflammato

  8. Slide 8: BL-1020: First in Class GABA-Enhanced Antipsychotic for Schizophrenia

    Slide 8: BL-1020: First in Class GABA-Enhanced Antipsychotic for Schizophrenia

    BL-1020: FIRST IN CLASS GABA- ENHANCED ANTIPSYCHOTIC FOR SCHIZOPHRENIA 8

  9. Slide 9: BL-1020 Target Product Profile

    Slide 9: BL-1020 Target Product Profile

    BL-1020 Target Product Profile • Indication: Schizophrenia – Other potential indications (e.g. Alzheimer’s) • Efficacy: FGA- First Generation Antipsychotics – Highly efficacious, similar to FGA and SGA SGA- Second Generation Antipsychotics • Safety: – Overall: clean safety profile; better than FGA &

  10. Slide 10: Schizophrenia Market and Unmet Medical Need

    Slide 10: Schizophrenia Market and Unmet Medical Need

    Schizophrenia Market and Unmet Medical Need • Chronic, severe, and disabling brain disorder affecting ~1% of the U.S. adult population* • Antipsychotic therapeutics recorded $13.6 billion in US sales in 2008 – Projected to stay stable through 2018** • Nearly all patients with schizophrenia qualify a

  11. Slide 11: BL-1020 Mode Of Action

    Slide 11: BL-1020 Mode Of Action

    BL-1020 Mode Of Action • BL-1020 addresses two key imbalances implicated in schizophrenia – Dopamine hyperactivity (many anti-psychotics block dopamine) – GABA hypoactivity (free GABA cannot cross the BBB) • BL-1020 MOA: – Dopamine antagonism – GABAergic activity 11

  12. Slide 12: Phase IIb EAGLE Trial Overview

    Slide 12: Phase IIb EAGLE Trial Overview

    Phase IIb EAGLE Trial Overview • Double blind, multi-center, 6-week study • Designed to determine the efficacy, safety and tolerability of BL-1020 in hospitalized patients with acute exacerbation of schizophrenia • Full GCP trial conducted under U.S. FDA IND at 40 sites in the USA, Europe and India

  13. Slide 13: EAGLE Trial Endpoints

    Slide 13: EAGLE Trial Endpoints

    EAGLE Trial Endpoints Efficacy endpoints comprised mean change from baseline in total score of: • Primary: − PANSS (Positive and Negative Symptom Scale) • Secondary: − CGI-S and CGI-C (Clinical Global Impression of Severity or Change) − Readiness to Discharge Questionnaire (RDQ) − Strauss Carpenter

  14. Slide 14: BL-1020 Meets Primary PANSS Endpoint

    Slide 14: BL-1020 Meets Primary PANSS Endpoint

    BL-1020 Meets Primary PANSS Endpoint PANSS Total Score Change Over Time Placebo BL-1020 10mg/day BL-1020 30mg/day Risperidone Change from Baseline (LSM) Week ANCOVA model: Change= Baseline Value Center Treatment (*p<0.05: compared with placebo) 14

  15. Slide 15: BACS Subscale Scores

    Slide 15: BACS Subscale Scores

    BACS Subscale Scores “Change on BACS (baseline to day 42): Effect size vs. Placebo m BL-1020 10mg m BL-1020 20-30 mg m Risperidone rerN OverallBACS "Verbal Memory Digit Sequencing Token Motor Verbal Fluency S Coding Tower of London Effect size is Cohen's d, based on difference in LS means

  16. Slide 16: BL-1020's GABAergic Activity Results in Cognitive Improvement

    Slide 16: BL-1020's GABAergic Activity Results in Cognitive Improvement

    BL-1020’s GABAergic Activity Results in Cognitive Improvement BL-1020 is effective in reversing cognitive impairment Selective GABAA antagonists block BL-1020’s effect on cognition 100 Initial phase Reversal phase responding 90 ## correct responding 80 70 60 *** *** *** 50 % of%correct 40 30 20 10 0

  17. Slide 17: Next Clinical Study – CLARITY Study

    Slide 17: Next Clinical Study – CLARITY Study

    Next Clinical Study – CLARITY Study • CLARITY Phase II/III trial commenced June 2011 – Randomized, double-blind, placebo-controlled – Aimed at determining acute (6 weeks) and long-term (6 months) anti-psychotic and cognitive efficacy, safety and tolerability of BL-1020 compared with placebo and Risp

  18. Slide 18: CLARITY Study Protocol

    Slide 18: CLARITY Study Protocol

    CLARITY Study Protocol Acute Chronic Phase Phase BL-1020 Titrate to MTD (15-35) BL-1020 Risperdal Titrate to MTD (2-6) Risperdal BL-1020 Placebo Risperdal Co-Primary: PANSS TREATMENT: 6 weeks Co-Primary: MATRICS/UPSA TREATMENT: 6 months 18

  19. Slide 19: BL-1020 Partnership Update

    Slide 19: BL-1020 Partnership Update

    BL-1020 Partnership Update • Reacquired North American rights from Cypress Bioscience – BioLineRx now holds all global rights to BL-1020 – Cypress to receive 1% royalty on global sales up to total cumulative amount of $80 million – Cypress to receive 10% of future one-time payments from out-licensin

  20. Slide 20: BL-1040: First-in-Class Myocardial Implant for Tissue Damaged by AMI

    Slide 20: BL-1040: First-in-Class Myocardial Implant for Tissue Damaged by AMI

    BL-1040: FIRST-IN-CLASS MYOCARDIAL IMPLANT FOR THE TREATMENT OF TISSUE DAMAGED BY AMI Out-licensed to Ikaria Holdings Inc. and being developed as IK-5001 20

  21. Slide 21: Current Treatment Methodologies and Unmet Medical Need

    Slide 21: Current Treatment Methodologies and Unmet Medical Need

    Current Treatment Methodologies and Unmet Medical Need Vessel occlusion Tissue damage Successfully treated No current treatment for with PCI and stents myocardial damage 21

  22. Slide 22: How Does BL-1040 Work?

    Slide 22: How Does BL-1040 Work?

    How Does BL-1040 Work? Infarct related artery (intra-vascular) injection Deposition into infarcted tissue Liquid to gel phase transition upon contact with infarcted tissue Phase transition at infarct area creates resorbable bioprosthetic scaffold providing mechanical support to damaged cardiac muscl

  23. Slide 23: BL-1040 Deposits in Damaged Tissue Following Intra-Coronary Injection

    Slide 23: BL-1040 Deposits in Damaged Tissue Following Intra-Coronary Injection

    BL-1040 Deposits in Damaged Tissue Following Intra-Coronary Injection Targeting mechanism: 1. Injection occurs in the infarct related artery 2. Capillary bed compromised secondary to ischemia allows inflow of BL-1040 3. Physiological condition of ischemic region enables liquid to gel transition Isch

  24. Slide 24: BL-1040 Prevents Structural Changes Following AMI

    Slide 24: BL-1040 Prevents Structural Changes Following AMI

    BL-1040 Prevents Structural Changes Following AMI Porcine AMI model, day 60 Dilated left Normal size ventricle left ventricle Normal LV Thin LV wall wall Untreated BL-1040 24

  25. Slide 25: BL-1040 Resorbs Within Six Weeks Following Injection

    Slide 25: BL-1040 Resorbs Within Six Weeks Following Injection

    BL-1040 Resorbs Within Six Weeks Following Injection Microscopic view of labeled BL-1040 (brown biotin staining) distribution in the scar tissue: BL-1040 resorption in scar Alginate resorption in the scar 60 40 % of scar p=0.0007 20 0 0 10 20 30 40 50 Days after injection Landa et al. Circulation 20

  26. Slide 26: BL-1040 Safe and Well-Tolerated in Pilot Clinical Trial Results

    Slide 26: BL-1040 Safe and Well-Tolerated in Pilot Clinical Trial Results

    BL-1040 Safe and Well-Tolerated in Pilot Clinical Trial Results • Clinical program based on extensive interaction with FDA (CDRH division) • Pilot study in Europe – completed January 2010 – 27 patients, safety and preliminary efficacy in patients with primary MI at high risk for LV remodeling • 9 si

  27. Slide 27: Ikaria BL-1040 Out-Licensing Transaction

    Slide 27: Ikaria BL-1040 Out-Licensing Transaction

    Ikaria BL-1040 Out-Licensing Transaction • Ikaria - proven expertise in drug and medical device development and singular focus on acute care • Terms: – $7 million upfront - received – $10 million first milestone - received February 2010 upon successful completion of pilot study – ~$115 million in ad

  28. Slide 28: BL-1040 Active Trial Program: Current Status and Next Steps

    Slide 28: BL-1040 Active Trial Program: Current Status and Next Steps

    BL-1040 Active Trial Program: Current Status and Next Steps Two partially overlapping trials, expected to commence in H2 2011 • First pivotal trial • Second pivotal trial − Protocol finalized − Meeting held with FDA to discuss protocol − Overall design − Overall design − Placebo controlled − Placebo

  29. Slide 29: BL-5010: Novel Formulation for Non-Surgical Removal of Benign Skin Lesions

    Slide 29: BL-5010: Novel Formulation for Non-Surgical Removal of Benign Skin Lesions

    BL-5010: NOVEL FORMULATION FOR NON-SURGICAL REMOVAL OF BENIGN SKIN LESIONS Phase I/II Complete 29

  30. Slide 30: BL-5010: Novel Formulation for Non-Surgical Removal of Skin Lesions

    Slide 30: BL-5010: Novel Formulation for Non-Surgical Removal of Skin Lesions

    BL-5010: Novel Formulation for Non-Surgical Removal of Skin Lesions • Positioning – Novel formulation for non-surgical removal of skin lesions • Status – Phase I/II clinical trial completed - positive results • Product highlights – Novel formulation of components in use in cosmetics and dermatology

  31. Slide 31: BL-5010 Phase I/II Clinical Trial Results Highlights

    Slide 31: BL-5010 Phase I/II Clinical Trial Results Highlights

    BL-5010 Phase I/II Clinical Trial Results Highlights • Safety – Good safety profile: no persistent irreversible adverse effects were observed at treated site • Efficacy – Lesion removal - the lesion fell off by day 30 in 96.7% of patients – Cosmetic outcome - most PIs and patients very satisfied wit

  32. Slide 32: Representative Pictures

    Slide 32: Representative Pictures

    Representative Pictures Pt. 20017 Screening Pt. 20017 day30 Pt. 20017 day1 Pt. 20017 day90 32

  33. Slide 33: BL-1021: New Chemical Entity for Neuropathic Pain

    Slide 33: BL-1021: New Chemical Entity for Neuropathic Pain

    BL-1021: NEW CHEMICAL ENTITY FOR NEUROPATHIC PAIN 33

  34. Slide 34: BL-1021: New Chemical Entity for Treatment of Neuropathic Pain

    Slide 34: BL-1021: New Chemical Entity for Treatment of Neuropathic Pain

    BL-1021: New Chemical Entity for Treatment of Neuropathic Pain • Indication: Neuropathic pain • Status: Phase I clinical trial to commence July 2011 • Product highlights: – Orally available small molecule – Anti-neuropathic profile demonstrated in vitro and in various animal models – Enhanced safety

  35. Slide 35: BL-1021 Pharmacological Profile

    Slide 35: BL-1021 Pharmacological Profile

    BL-1021 Pharmacological Profile Efficacy Safety • Affects key mediators of • Significantly lower affinity for pain M1-5 muscarinic and H1 histaminergic receptors – Inhibits norepinephrine and compared with drugs in class serotonin re-uptake • No affinity for adrenergic and – Blocks a wide range of s

  36. Slide 36: BL-1021 Reduces Thermal Hyperalgesia in Chung Model of Neuropathic Pain

    Slide 36: BL-1021 Reduces Thermal Hyperalgesia in Chung Model of Neuropathic Pain

    BL-1021 Reduces Thermal Hyperalgesia in Chung Model of Neuropathic Pain 1h post administration 35.0 * # 33.0 31.0 Paw Withdrawal Latency (Sec) 29.0 27.0 25.0 23.0 21.0 19.0 17.0 15.0 BL-1021 Nortriptyline Pregabalin Gabapentin vehicle 13.2mg/kg 50mg/kg 15mg/kg 30mg/kg 36

  37. Slide 37: BL-1021 Reduces Tactile Allodynia in CCI Model of Neuropathic Pain

    Slide 37: BL-1021 Reduces Tactile Allodynia in CCI Model of Neuropathic Pain

    BL-1021 Reduces Tactile Allodynia in CCI Model of Neuropathic Pain Day 14 of Administration 280 ** * ## 260 ** # ## 240 220 * AUC 200 180 160 140 Vehicle BL-1021 BL-1021 BL-1021 Gabapentin Morphine 5mg/kg 10mg/kg 20mg/kg 100mg/kg 3mg/kg s.c. *p<0.05 vs. Vehicle, **p<0.01 vs. Vehicle, #p<0.05 vs. BL-

  38. Slide 38: RotaRod Test Confirms that BL-1021 is Not Sedative

    Slide 38: RotaRod Test Confirms that BL-1021 is Not Sedative

    RotaRod Test Confirms that BL-1021 is Not Sedative 350 300 250 time on RotaRod (sec) 200 * 150 100 50 ** 0 DDW morphine BL-1021 79.2 Nortriptyline 60 mg/kg mg/kg * P<0.05 **P<0.01 vs. DDW control 38

  39. Slide 39: Clinical Trial Update

    Slide 39: Clinical Trial Update

    Clinical Trial Update • Phase I – FPI June 2011 • Study objectives: to assess the safety, tolerability and pharmacokinetics in healthy volunteers • Design: randomized, double-blind, placebo-controlled, single center study • Will be conducted in two stages: – Single ascending dose study (4 cohorts: 1

  40. Slide 40: BL-7040: Oligonucleotide for Inflammatory Bowel Disease

    Slide 40: BL-7040: Oligonucleotide for Inflammatory Bowel Disease

    BL-7040: OLIGONUCLEOTIDE FOR INFLAMMATORY BOWEL DISEASE 40

  41. Slide 41: BL-7040: Oligonucleotide for Treatment of Inflammatory Bowel Disease

    Slide 41: BL-7040: Oligonucleotide for Treatment of Inflammatory Bowel Disease

    BL-7040: Oligonucleotide for Treatment of Inflammatory Bowel Disease • Indication: Inflammatory Bowel Disease (IBD) • Status: Phase II clinical trial expected to begin Q1 2012 • Product highlights: – Orally available oligonucleotide – Anti-inflammatory effect demonstrated in vitro and in various ani

  42. Slide 42: Unique Funding Programs

    Slide 42: Unique Funding Programs

    UNIQUE FUNDING PROGRAMS 42

  43. Slide 43: Unique Risk-Reduction Funding Programs

    Slide 43: Unique Risk-Reduction Funding Programs

    Unique Risk-Reduction Funding Programs BioLine Innovations Jerusalem • Only Israeli biotech incubator supported by Office of Chief Scientist, Israeli Trade Ministry (OCS) – $12 million received, plus additional $5 million under regular OCS funding track – Enhanced financial support, up to 85% of fir

  44. Slide 44: Early Development Program Pipeline

    Slide 44: Early Development Program Pipeline

    Early Development Program Pipeline $6 million program to identify and advance research-stage innovative projects 44

  45. Slide 45: Corporate

    Slide 45: Corporate

    CORPORATE 45

  46. Slide 46: Financial Summary

    Slide 46: Financial Summary

    Financial Summary • 2010 Results − Revenues – NIS 113.2 million (~$32.5 million) − Operating profit – NIS 13.1 million (~$3.8 million) − Net profit – NIS 7.4 million (~$2.1 million) − Shares Outstanding – 123.5 million • Available cash as of June 30, 2011 - ~$33 million − Cash expected to last throu

  47. Slide 47: IP Portfolio and Strategy

    Slide 47: IP Portfolio and Strategy

    IP Portfolio and Strategy • Exclusive license to > 22 patent families with >18 issued patents and 100 patent applications pending worldwide • Proprietary protection of technology, inventions and improvements • BL-1020 – Exclusive license to five patent families pertaining to BL-1020 molecule, pharma

  48. Slide 48: IP Portfolio and Strategy (cont.)

    Slide 48: IP Portfolio and Strategy (cont.)

    IP Portfolio and Strategy (cont.) • BL-1021 – Exclusive license to two patent families pertaining to BL-1021 molecule, pharmaceutical compositions and methods of use; national members are pending worldwide – Patent protection through at least 2022 (for composition) and at least 2027 (for method of u

  49. Slide 49: Management Team

    Slide 49: Management Team

    Management Team Kinneret Savitsky, PhD CEO Former VP R&D at Compugen (NASDAQ: CGEN) Moshe Phillip, MD VP of Clinical/Medical Affairs Vice Dean of TAU Medical School Philip Serlin, CPA, MBA CFO/COO Former CFO at Kayote Networks, Tescom; Head of US/SEC Dept at Deloitte Israel, Senior Acct at SEC in Wa

  50. Slide 50: Scientific Advisory Board

    Slide 50: Scientific Advisory Board

    Scientific Advisory Board Aaron Ciechanover, MD, PhD Nobel Prize Laureate; Technion Institute Aliza Eshkol, PhD Serono David Ladkani, PhD Teva Pharmaceuticals Moshe Phillip, MD BioLineRx Yaakov Naparstek, MD Hadassah University Hospital Itamar Shalit, MD Schneider Children’s Medical Center Yosef Yar

  51. Slide 51: Company Milestones Through End of 2013

    Slide 51: Company Milestones Through End of 2013

    Company Milestones Through End of 2013 BL-1020 - Schizophrenia BL-5010 – Skin Lesions • CLARITY trial commenced June • Clinical, regulatory, business 2011 evaluation • Results expected Q1 2013 • Partnering transaction or Phase III trial in 2012 BL-1040 – Cardiac remodeling BL-1021 – Neuropathic pain

  52. Slide 52: BioLineRx Summary

    Slide 52: BioLineRx Summary

    BioLineRx Summary • Clinical-stage pipeline momentum – 5 clinical stage assets • Deep and advancing preclinical pipeline – One program anticipated to enter clinic every 12-24 months – 8 additional programs at different clinical and pre-clinical stages for various indications – 4-6 additional program

  53. Slide 53: Bench to Bedside to Partner

    Slide 53: Bench to Bedside to Partner

    Benchto Beduideto Patner BIOLINEM><

Source: Internet Archive copy of biolinerx.com

More decks from BioLineRX Ltd.

All 37 BioLineRX decks